Evidence map›Paper›PMID 31659546›Full record

ArticleEJNMMI radiopharmacy and chemistry2019

Development and implementation of ISAR, a new synthesis platform for radiopharmaceutical production.

Christopher Frank, Georg Winter, Fredrik Rensei, Victor Samper, Allen F Brooks, Brian G Hockley, Bradford D Henderson, Christian Rensch, Peter J H Scott

Open access · goldAbstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. A Reliable Production System of Large Quantities of [Molecules (Basel, Switzerland) · 2023
    Article
  3. Production of [Molecules (Basel, Switzerland) · 2022
    Article
  4. Article
  5. Improved Synthesis of [ACS medicinal chemistry letters · 2020
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Christopher FrankGE Healthcare, Oskar-Schlemmer-Str. 11, 80807, Munich, Germany. Christopher.Frank@ge.com.
Georg WinterGE Healthcare, Oskar-Schlemmer-Str. 11, 80807, Munich, Germany.
Fredrik RenseiGE Healthcare, Uppsala, Sweden.
Victor SamperGE Additive, Garching near Munich, Germany.
Allen F BrooksDepartment of Radiology, University of Michigan, 2276 Medical Science Bldg I, SPC 5610, Ann Arbor, MI, 48109, USA.
Brian G HockleyDepartment of Radiology, University of Michigan, 2276 Medical Science Bldg I, SPC 5610, Ann Arbor, MI, 48109, USA.
Bradford D HendersonDepartment of Radiology, University of Michigan, 2276 Medical Science Bldg I, SPC 5610, Ann Arbor, MI, 48109, USA.
Christian RenschGE Additive, Garching near Munich, Germany.
Peter J H ScottDepartment of Radiology, University of Michigan, 2276 Medical Science Bldg I, SPC 5610, Ann Arbor, MI, 48109, USA. pjhscott@med.umich.edu.ORCID http://orcid.org/0000-0002-6505-0450
University of Michigan · USGeneral Electric (Spain) · ESHealthcare in Sweden · SESiemens Healthineers (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPET radiopharmaceutical development and the implementation of a production method on a synthesis module is a complex and time-intensive task since new synthesis methods must be adapted to the confines of the synthesis platform in use. Commonly utilized single fluid bus architectures put multiple constraints on synthesis planning and execution, while conventional microfluidic solutions are limited by compatibility at the macro-to-micro interface. In this work we introduce the ISAR synthesis platform and custom-tailored fluid paths leveraging up to 70 individually addressable valves on a chip-based consumable. The ISAR synthesis platform replaces traditional stopcock valve manifolds with a fluidic chip that integrates all fluid paths (tubing) and valves into one consumable and enables channel routing without the single fluid bus constraint. ISAR can scale between the macro- (10 mL), meso- (0.5 mL) and micro- (≤0.05 mL) domain seamlessly, addressing the macro-to-micro interface challenge and enabling custom tailored fluid circuits for a given application. In this paper we demonstrate proof-of-concept by validating a single chip design to address the challenge of synthesizing multiple batches of [

resultsISAR was installed at an academic PET Center and used to manufacture [

conclusionsISAR represents a new paradigm in radiopharmaceutical production. Through a new system architecture, ISAR integrates the principles of microfluidics with the standard volumes and consumables established in PET Centers all over the world. Proof-of-concept has been demonstrated through validation of a chip design for the synthesis of [

Indexed as

[13N]ammoniaAutomationLab on a chipMicrofluidicsMyocardial perfusion imaging

Identifiers

PMID31659546
PMCPMC6751239
OpenAlexW2973887603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.